Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 58

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 58
---
 such date, with the average exercise prices at $0.31 per share, of which options to purchase 3,347,500 Common Stock were vested 
 as of such date;                                                                                                                      |

| ● | 2,930,000 Common Stock                                                          
 reserved for future issuance under our 2021 Global Share Incentive Plan (2021). |

| ● | 6,372,265 Common Stock                                                                                                                
 issuable upon the exercise of our outstanding warrants with the average exercise price of $1.16 per share, exercisable until December 
 31, 2026;                                                                                                                             |

<div align='center'>32

DILUTION</div>

If you purchase shares underlying the Units
offered by the Company in this Primary Offering, you may experience dilution to the extent of the difference between the price per share
you pay in this Primary Offering and the net tangible book value per share of our Common Stock immediately after this offering. The net
tangible book value of our Common Stock on March31, 2025 was approximately $ 4.6 million, or approximately $0.08 per share. Net tangible
book value per share is equal to the amount of our total tangible assets, less total liabilities, divided by the aggregate number of
shares of our Common Stock outstanding.

After giving effect to the assumed sale by us of 3,125,000 shares underlying the Units (assuming the sale of all securities offered hereby, at the fixed public offering price of $3.20 per Unit, and assuming no exercise of the IPO Warrants issued in connection with this offering), our as adjusted net tangible book value as of March 31, 2025 would have been approximately $9.0 million, or approximately $0.14 per share. This represents an immediate increase in net tangible book value of approximately $0.06 per share to existing stockholders and an immediate dilution of approximately $3.06 per share to new investors purchasing Units in this offering. The following table illustrates this per share dilution:

| Assumed initial public offering price per Unit                                    |     |   |      |     | $ | 3.20 |
| Historical net tangible book value per share as                                   
 of March 31, 2025                                                                 |     | $ | 0.08 |     |   |      |
| Increase in net tangible                                                          
 book value per share attributable to new investors participating in this offering |     | $ | 0.06 |     |   |      |